Uniondale, NYNCT05562791Now EnrollingIRB Ready

Bladder Cancer Clinical Trial in Uniondale, NY

Access cutting-edge bladder cancer treatment through this clinical trial at a research site in Uniondale. Study-provided care at no cost to qualified participants.

Sponsored by Memorial Sloan Kettering Cancer Center

Quick Self-Assessment

See if you qualify for this Uniondale location

Preparing your pre-screening questions…

Expert Care in Uniondale

Access bladder cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related bladder cancer treatment provided free

Apply for This Uniondale Location

Check if you qualify for this bladder cancer clinical trial in Uniondale, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Uniondale

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Uniondale site if eligible
  4. 4Begin participation

About This Bladder Cancer Study in Uniondale

The purpose of this study is to see whether 68Gallium PSMA-PET/CT scans are an effective way to detect sites of cancer in people with metastatic bladder cancer or skin cancer. The study researchers want to learn if a 68Gallium PSMA PET/CT scan will work better, the same, or not as well as the PET/CT scans doctors usually use for imaging bladder cancer or skin cancer (FDG-PET/CT scan).

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

for Urothelial Carcinoma Cohort:
Patients with histologically confirmed metastatic urothelial carcinoma with extrapelvic nodal and/or visceral sites of disease (including lung, liver, bone, or soft tissue)
At least 1 lesion assessable by FDG PET/CT according to RECIST and PERCIST guidelines where applicable, that are determined suspicious for metastasis by an MSKCC attending radiologist or nuclear medicine physician.
Karnofsky performance status ≥50% (or ECOG/WHO ≤2)
Participant is ≥18 years of age
Patient must be able to understand and is willing to sign a written informed consent document Inclusion Criteria for Melanoma Cohort:
Patients with histologically confirmed metastatic melanoma
At least 1 metastatic lesion assessable by CT or FDG PET/CT according to RECIST that is determined to be suspicious for metastasis by an MSKCC attending radiologist or nuclear medicine physician
Participant is \>= 18 years of age
Patient must be able to understand and is willing to sign a written informed consent document

Exclusion Criteria

for Urothelial Carcinoma Cohort:
Patients with pelvic node-only metastatic disease. If the patient has lymph node only disease, at least one PET-assessable node must be located outside of the pelvis
Patients with bone only disease
Unable to lie flat, still, or to tolerate a PET scan
Patient undergoing active treatment for non-urothelial malignancy, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized.
Patients on a therapeutic clinical trial where PSMA imaging would interfere with the conduct of the trial
Patients undergoing active surveillance with a known history of non-urothelial malignancies
Women who are pregnant. All women of childbearing potential must have a documented negative pregnancy test. Exclusion Criteria for Melanoma Cohort:
Unable to lie flat, still, or tolerate PET scan.
Patient is on another therapeutic trial where PSMA imaging would interfere with the conduct of the trial.
Women who are pregnant. All women of childbearing potential must have a documented negative pregnancy test.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Uniondale?

Yes, this clinical trial (NCT05562791) has an active research site in Uniondale, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Bladder Cancer Treatment Options in Uniondale, NY

If you're searching for bladder cancer treatment options in Uniondale, NY, this clinical trial (NCT05562791) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Uniondale research site is actively enrolling participants for this clinical trial. You'll receive care from experienced bladder cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all bladder cancer clinical trials near you to find additional studies recruiting in your area.

More Bladder Cancer Trials in Uniondale, NY

See all bladder cancer clinical trials recruiting in Uniondale — not just this study.

Browse Bladder Cancer Trials in Uniondale

Ready to Join in Uniondale?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Uniondale, NY